Mitsubishi UFJ Asset Management Co. Ltd. Buys New Holdings in Boston Scientific Corporation $BSX

Posted by Brenda Bartman on Aug 18th, 2026

Boston Scientific logo Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Boston Scientific Corporation (NYSE:BSX – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,617,472 shares of the medical equipment provider’s stock, valued at approximately $154,394,000. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.25% of Boston Scientific at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the business. Norges Bank bought a new position in shares of Boston Scientific during the 4th quarter worth about $2,199,395,000. Bank of New York Mellon Corp bought a new stake in Boston Scientific in the second quarter valued at about $339,031,000. Assenagon Asset Management S.A. raised its position in Boston Scientific by 133.6% in the first quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock worth $631,135,000 after purchasing an additional 5,751,760 shares in the last quarter. Janus Henderson Group PLC raised its position in Boston Scientific by 31.0% in the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after purchasing an additional 3,907,981 shares in the last quarter. Finally, Maverick Capital Ltd. bought a new position in Boston Scientific during the fourth quarter worth about $280,735,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

BSX has been the topic of a number of recent research reports. Royal Bank Of Canada decreased their price objective on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Mizuho cut their target price on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a research report on Friday, June 12th. Finally, UBS Group dropped their price objective on Boston Scientific from $74.00 to $67.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $71.62.

Get Our Latest Report on BSX

Boston Scientific Stock Down 0.7%

Shares of BSX opened at $51.46 on Tuesday. The company has a market capitalization of $74.58 billion, a P/E ratio of 20.83, a PEG ratio of 1.13 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The business’s 50 day simple moving average is $46.12 and its 200-day simple moving average is $58.81.

Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the firm posted $0.75 EPS. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a share buyback plan on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Insider Activity at Boston Scientific

In related news, CEO Michael F. Mahoney acquired 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 202,122 shares of company stock worth $9,813,931. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Profile

(Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.